Choosing From an Expanding Toolbox

Not long ago, the refractive surgery consultation was relatively straightforward. A patient seeking freedom from glasses generally fit into one of a few familiar categories, and the discussion centered on LASIK, PRK, or cataract surgery. Today’s conversations are markedly different. The toolbox has expanded—not just in terms of the number of procedures available but also in the sophistication with which we surgeons can personalize treatment. That progress is something worth celebrating, but it also comes with a new responsibility.

Ironically, the greatest challenge in refractive surgery may no longer be working with technological limitations or performing safe surgery. It may be decision-making.

Corneal procedures continue to evolve with advances in laser technology, ablation patterns, and lenticule extraction. Lens-based surgery has expanded through improvements in phakic IOLs, and refractive lens exchange has emerged as an option for our precataract patients. Pharmacologic therapies offer patients additional choices, particularly for the management of presbyopia. At the same time, improvements in diagnostic instruments and ocular surface management have fundamentally changed how we evaluate and prepare patients before they enter the OR.

Each innovation adds another instrument to our toolbox. None, however, is a replacement for sound clinical judgment and appropriate patient education and guidance.

The most important evolution in refractive surgery may be a philosophical one. Increasingly, our goal is not to determine which procedure is the best but rather which combination of technologies and treatments is best suited to a particular patient. A young patient with myopia and thin corneas, a patient with presbyopic emmetropia hoping to avoid surgery, a patient with high myopia seeking the highest quality of vision possible, and a patient with subtle ocular surface disease all require different approaches. 

CRST’s cover series this month reflects that evolution. Should presbyopia drops be viewed as a competitor to surgery or a valuable bridge and adjunct that help patients navigate different stages of their aging eyes? Can ray-tracing planning deliver clinically meaningful improvements beyond conventional wavefront-guided treatments? Has the expanding role of phakic IOLs created a new sweet spot for patients who previously had limited options? As keratorefractive procedures mature, is lenticule extraction beginning to challenge LASIK in meaningful ways? Perhaps most importantly, why should optimization of the ocular surface remain the first tool we reach for before considering any refractive intervention?

Taken together, this issue's contributions illustrate that refractive surgery is no longer defined by a single procedure. Instead, it is defined by an increasingly sophisticated ecosystem of technologies, diagnostics, pharmaceuticals, and surgical options that allows us to tailor treatment to each patient.

As exciting as these advances are, they also remind us that innovation alone is never enough. Every new technology should improve our ability to deliver better outcomes—not simply provide another option. The expanding refractive toolbox is valuable only if we understand both how and when to use it.

Ultimately, that is what distinguishes great refractive surgeons. Our expertise is measured less by the number of procedures we perform than by our ability to select the right intervention—or sometimes no intervention at all—for the patient sitting in front of us.

As you read this edition of CRST, I hope the articles encourage you to reassess your toolbox, explore emerging technologies with both curiosity and healthy skepticism, and continue refining your individualized decision-making. 

Ophthalmology is not only a science but also the art of delivering the best possible patient care. Our toolbox has never been larger, and our opportunity to improve patients’ lives has never been greater.